Showing results (71-80 of 125) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerXavier Pivot, Alexey Manikhas, Bogdan Żurawski, et al.
JCO Global Oncology|February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in OncologyConcetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
Breast Cancer Research : BCR|September 20, 2019
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trialBarbara Adamo, Meritxell Bellet, Laia Paré, et al.
The Breast Journal|February 9, 2019
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE studyLuis Manso, Fernando Moreno Antón, Yann Izarzugaza Perón, et al.
The Lancet. Oncology|April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
The New England Journal of Medicine|May 16, 2019
Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast CancerFabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trialMafalda Oliveira, Eva Ciruelos, Guillermo Villacampa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2016
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST SubstudyMeritxell Bellet, Kathryn P Gray, Prudence A Francis, et al.
Pageof 13